Malignant tumors of parotid gland are mainly treated by surgery, and the extent of surgical resection should be decided according to the size of the lesion, the type of pathology, and the degree of malignancy. Low-grade malignancy only requires local extended resection, while adjuvant radiotherapy, systemic adjuvant chemotherapy and immunotherapy should be given to highly malignant after local extended resection. There are two surgical approaches: the anterior-to-posterior approach, in which the parotid duct is separated first, and the posterior-to-front approach, in which the common trunk of the facial nerve is dissected first. The former is suitable for mixed tumors under the ear, and the latter method is suitable for mixed tumors in the anterior part of the parotid gland. Radiotherapy is used as one of the comprehensive treatments in order to minimize postoperative recurrence. Radiotherapy can be given to patients with highly malignant pathological types, or those who have not been operated thoroughly enough, those who are suspected to have residual tumor tissues, those who have retained the facial nerve in tight adhesion with the tumor, and those who have a late stage of the disease, which can significantly improve the survival rate after surgery and reduce recurrence. Chemotherapeutic drug therapy for parotid malignant tumors is unlike malignant lymphoma and squamous carcinoma, which have systematic and standardized therapeutic treatment plans. Effective drugs include cisplatin, methotrexate, fluorouracil, doxorubicin, etc. Chemotherapy is not effective in the treatment of parotid gland tumors, and it is only used as one of the comprehensive adjuvant treatments.